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Introduction: Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction
and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX)
in chronic or recurrent CPPD arthropathy.
Methods: Patients with CPPD arthropathy were randomized to receive either weekly subcutaneous injections of
15 mg/week of MTX or placebo (PBO) for three months, in a double-blind, crossover randomized controlled trial.
Inclusion criteria comprised definite CPPD disease, recurrent arthritis or persistent polyarthritis, and an insufficient
response to NSAIDs, glucocorticoids or colchicine. The primary outcome was an improvement in the disease activity
scores based on 44 joints (DAS44). The analysis was performed on an intent-to-treat basis.
Results: We randomized 26 patients, and compared 25 treatment periods on MTX with 21 treatment periods on
PBO. Baseline characteristics were balanced between the groups. The evolution of the DAS44 was not statistically
significantly different between groups (median DAS44 decreased by −0.08 on MTX versus −0.13 on PBO, after three
months, P = 0.44). Furthermore, pain levels remained stable in both groups (median change in VAS Pain −1 unit on
MTX and 0 on PBO, P = 0.43), and none of the secondary outcomes was significantly different between the two
groups. Minor adverse events (AE) did not differ in frequency between the groups, but the only serious AE occurred
on MTX (bicytopenia).
Conclusions: The results of this trial with MTX in this older population with chronic or recurrent CPPD arthropathy
suggest no strong effect of MTX on disease activity.
Trial registration: EudraCT No: 2007-003479-37. Registered 26 April 2008Introduction
Calcium pyrophosphate deposition (CPPD) disease is a
very common and occasionally severe arthropathy asso-
ciated with chondrocalcinosis. Chondrocalcinosis is itself
a metabolic condition due to CPPD, particularly fre-
quent in the second half of life. It can be asymptomatic,
at least at the beginning, but various forms of arthropathies
develop in affected individuals. Symptomatic presentations
include acute CPP arthritis, sometimes called pseudogout,
and a chronic arthropathy, generally recurrent, associating* Correspondence: Pierre-Andre.Guerne@hcuge.ch
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stated.osteoarthritis (OA) and CPPD [1]. Recurrent acute CPP
arthritis and chronic recurrent CPP arthropathy can lead to
severe joint destruction, sometimes very rapidly.
Currently, no specific treatment has demonstrated effi-
cacy to prevent or slow CPP deposition [2]. Acute inflam-
mation induced by CPPD crystals can be nonspecifically
treated by nonsteroidal anti-inflammatory agents (NSAIDs),
glucocorticoids or colchicine, but these symptomatic treat-
ments are very often ineffective, particularly in recurrent or
chronic cases [2]. Furthermore, these agents are frequently
not tolerated or contraindicated in older patients, the popu-
lation most frequently affected by chondrocalcinosis. More
importantly, none of the available treatments proved able
to stop gradual joint damage due to chondrocalcinosis.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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with biologic anti-interleukin 1 (IL-1) agents [3,4], but
these agents are extremely expensive and not reim-
bursed by most health systems or insurances for
this indication.
At low doses, methotrexate (MTX) is a potent anti-
inflammatory agent, considered the gold standard therapy
for many inflammatory arthritides. MTX could conceptu-
ally be effective in CPP arthropathies since it interferes
with glutathione metabolism, decreasing cell recruitment
to the inflamed joint and promoting the release of the en-
dogenous anti-inflammatory mediator adenosine and IL-
1Ra [5]. Given its good safety profile and low cost, MTX
could represent an interesting therapeutic option, particu-
larly for patients resistant to classic anti-inflammatory
treatments. Two case series suggested that MTX is a safe
and effective therapeutic alternative for CPPD arthropa-
thy refractory to standard therapy [6,7], but were con-
tradicted later by a small French case series [8]. To date,
no controlled study has examined the impact of MTX
in refractory CPP arthropathy. We therefore conducted
a randomized controlled trial to test the efficacy of




This was a double-blind, crossover randomized con-
trolled trial. Patients were randomized to receive either
MTX or placebo (PBO) by subcutaneous (sc) injection
during an initial treatment period of three months,
followed by a ‘wash-out’ phase of two months and a
crossover second treatment period of three months
(Figure 1). Period durations of three months’ treatment
were selected to capture the relatively slow-acting anti-
inflammatory effects of MTX and usual naturalFigure 1 Study design. This was a double-blind, crossover randomized co
(MTX) or placebo (PBO) during an initial treatment period of three months,
treatment period of three months. The T + X (↓) represent monthly assessm
clinical examination.fluctuations of the disease. Once monthly, patients were
examined, asked to fill out questionnaires and had
routine blood tests.
Study population and recruitment
We intended to study the subset of CPPD arthropathy
patients presenting with recurrent clinical manifestations
of acute mono- or oligoarthritis (‘pseudogout’), or persist-
ent polyarthritis. We enrolled all consecutive patients
from the Rheumatology Departments of several university
hospitals (Geneva, Dublin, Zurich) and regional hospitals
(La Chaux-de-Fonds and Yverdon) who met the inclusion
criteria and accepted to enter the study. The inclusion
criteria were:
 Definite CPPD disease using the McCarty diagnostic
criteria [9].
 Recurrent mono- or oligoarthrits (‘pseudogout’)
(at least three flares/six months) or persistent
polyarthritis.
 Unsatisfactory response to at least one NSAID or
low-dose glucocorticoids (defined by the patient),
OR contraindication to NSAIDs and glucocorticoids
(defined by the physician).
The exclusion criteria were:
 A contraindication to MTX treatment: hepatic
failure, important alcohol consumption, severe renal
failure, hematological disease, acute infection.
 A diagnosis of an alternative rheumatic condition:
rheumatoid arthritis, connective tissue disease,
psoriatic arthritis, gout or any other chronic or
recurrent disease associated with oligo- or polyarthritis.
 Inability to fill out a questionnaire in the
local language.ntrolled trial. Patients were randomized to receive either methotrexate
followed by a ‘wash-out’ phase of two months and a crossover second
ents since randomization; the status (↑) represent medical visits with a
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(Geneva, Lausanne, Bern, Zurich, Switzerland and Mater
Misericordiae University Hospital, Dublin, Ireland) and
the Swiss federal health authorities (Swissmedic). In-
formed consent was obtained from all participants. The
trial was registered (EudraCT N°: 2007-003479-37,
ISRCTN79343755) [10].
Randomization/blinding
Patients were randomized to either MTX or PBO in bal-
anced blocks of six by means of a random number gen-
erator. The medication codes were kept in sealed
envelopes until the end of the study. Both patients and
the investigators were blinded to the treatment group
assignment.
Intervention
Patients were randomized to receive either MTX or
PBO during an initial treatment period of three months,
followed by a ‘wash-out’ period of two months, and a
subsequent treatment period of three months with the
alternative regimen. Patients were started on MTX ther-
apy with 7.5 mg the first week, which was increased to
15 mg/week if tolerated. All patients also simultan-
eously received folic acid supplementation (5 to 10 mg/
week) to reduce side effects, as recommended. Patients
received their first sc MTX injection by a nurse and
were taught how to perform sc injections themselves.
Subsequent MTX injections were self-administered with
commercially available pre-filled syringes (Metoject™,
Gebro Pharma AG, Liestal, Switzerland) [11]. Identical
pre-filled syringes containing NaCl 0.9% were produced
and packed by the hospital’s pharmacy. New medica-
tions were provided at each visit and exchanged for
unused medications, to assess compliance by syringe
count.
Patients were allowed to use concomitant medica-
tions as judged best by their physicians, without modi-
fications during the study (from three days before T0,
to T +8). In addition, treatment of CPPD arthropathy
flares with a three-day course of NSAIDs, a three-day
course of oral glucocorticoids (≤30 mg/d of equivalent
prednisolone) or a three-day course or increase of colchi-
cine was allowed. Intra-articular injections of glucocorti-
coids or high doses of oral glucocorticoids (>30 mg/day)
were not allowed.
Outcome measures
The primary outcome was disease activity score based
on 44 joints (DAS44). The DAS44 is a validated as-
sessment tool of disease activity in rheumatoid arth-
ritis (RA) that has been used in many other chronic
arthritides. The DAS44 is a composite outcome meas-
ure including the number of swollen joints, thenumber of tender joints and the erythrocyte sedimen-
tation rate (ESR).
Computation of the DAS44 [12]:
DAS44 ¼ 0:54√ Tender countð Þ
þ 0:065√ Swollen countð Þ þ 0:33 ln ESRð Þ
þ 0:007 patient assessmentð Þ
The number of tender and swollen joints was assessed
by the physicians at the beginning and at the end of each
treatment period during the medical examination. ESR
was measured at regular intervals on each blood test.
General health was evaluated using a Lickert scale ran-
ging from 0 to 10 by the physician.
Secondary outcomes included the number of acute
arthritis flares for the acute recurrent forms, and disease
and pain levels (visual analog scale (VAS)) for the chronic
forms, which have been shown to be sensitive to change in
other arthritides
– Acute arthritis flares: Acute arthritis flares
(‘pseudogout flares’) are an important outcome as
these are one of the most easily recognized concerns
of patients. However, flares have not yet been well
defined in the arthritis literature [13]; we therefore
only recorded the number of subjective arthritis
flares and let patients judge what is or is not a ‘flare’
or an ‘attack’. We considered transient increases in
concomitant glucocorticoids as a flare equivalent.
– Pain: Pain was measured using a VAS of the target
joints.
– Safety: We monitored MTX side effects according
to published guidelines [14]. All patients were
required to have a recent blood test prior to
enrollment to check liver function tests, hepatitis
serology (<1 year), blood cells and renal function. A
baseline chest X-ray was also performed. All
patients had their liver function tests, blood cell
count and creatinine tested at monthly intervals.
Other potential side effects were monitored at
monthly intervals. Among others, patients were
specifically asked about nausea, vomiting, abdominal
pain, diarrhea, cutaneous affections, mucous
ulcerations, cough and dyspnea.
– Other secondary outcomes: Included patient’s
global assessment, function of the target joints, ESR
and serologic markers of inflammation (blood tests),
duration of morning stiffness, number of tender and
swollen joints, number of analgesic pills, cumulative
dose of glucocorticoids, NSAIDs or colchicine and
safety [13]. Patient’s global assessment of their
general health was evaluated using a Lickert scale
ranging from 0 to 10. Functional impairment were
determined by asking the patient to assess function
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possible, 1 = weight bearing possible, 0 = painless
full function [13]). We also recorded the length of
morning stiffness in minutes, and number of
analgesic, and anti-inflammatory pills taken during
the previous week. The type of clinical presentation
of CPPD arthropathy was based on the number of
synovitic joints on the physical examination during
the three-month treatment period: one swollen joint
was classified as a monoarticular presentation,
between two and four swollen joints as an
oligoarticular presentation, and more than four
swollen joints as a polyarticular presentation. The
persistence of the clinical presentation was based on
the assessment of the enrolling physician (presence
of pseudogout flares) and the duration of patient’s
physical impairment by his arthritides (>50% of days
impaired classified as chronic arthropathy).
Analysis
We calculated the sample size based on published data on
DAS44 changes in trials with MTX in RA, with the goal of
being able to detect a difference at least as large as the ef-
fect size of a moderate clinical response (0.6 points,
EULAR response criteria) [15]. Assuming a matched ana-
lysis (crossover design) and a type one error of 5%, 28
pairs would be needed to reject the null hypothesis with a
statistical power of 80%.
Efficacy analyses were performed on the intent-to-treat
basis. Patients lost to follow-up after enrollment were
assumed not to have benefitted from the intervention
and a last observation carried over procedure was used
to impute the missing follow-up assessments. Individual
questionnaire scores, measured at monthly intervals,
were correlated and thus an analysis for repeated meas-
ure analysis was performed. It is not known precisely
when the therapeutic efficacy of MTX emerges in CPPD
arthropathy. Based on our pilot study [6], we estimated
that the therapeutic efficacy would appear within the
three first months after treatment initiation. In order to
analyze the DAS44 responses over time for both groups
(PBO and MTX), we use a marginal longitudinal model,
which consists of modeling parametrically the marginal
mean of the responses as well as the correlations be-
tween individuals. Since both groups are similar at base-
line by design, the marginal expectation of the response
depends only on a group effect (MTX vs. PBO), a quad-
ratic time trend specific to each period (in order to cap-
ture the natural evolution over time), and the DAS44 at
baselines (T0 and T +5, see Figure 1), and an interaction
period - treatment group [16].
We tested the possibility of a carry-over effect for pa-
tients who received MTX as their first treatment by add-
ing the treatment sequence into the model. We alsoanalyzed the possibility of effect modification by type of
CPPD arthropathy (monoarticular vs. polyarticular pres-
entation). All analyses were conducted with the R statis-
tical software (R version 2.15.2) [17].
Results
Forty-nine patients were screened for participation in the
trial, and after a medical assessment, 26 patients were ran-
domized (Figure 2). Seven patients did not complete the
whole trial; the most common reason for discontinuation
was a transaminase elevation above three times the nor-
mal values. The baseline characteristics at the initiation of
the trial treatment were balanced (Table 1). Subjects
ranged from 46 to 84 years (median = 71, IQR (54.5 to
76.0), mean = 66.4 ± 12.8) of age and were all Caucasian.
Disease activity, as measured by the DAS44 improved
over time (P = 0.005) but was not significantly improved
by treatment with MTX. As for the secondary outcomes,
none of the other secondary outcomes improved signifi-
cantly by treatment with MTX (Table 2, Figure 3).
We also examined the possibility of an effect modifica-
tion by the type of CPPD arthropathy (monoarticular
presentations vs. polyarticular presentations) and found
no evidence that MTX was more effective in patients
with polyarticular presentation (test for effect modifica-
tion, P = 0.27).
During the study follow-up, 35 adverse events (AEs)
were reported, 16 on MTX and 18 on PBO (P = 0.81) and
1 during the wash-out period. However, more patients
dropped out on MTX than on PBO (5 vs. 0), mostly for
common AE related to MTX. One serious AE was ob-
served on a patient on methotrexate: an acute bicytopenia,
which imposed hospitalization, fortunately without per-
manent damage.
Discussion
This randomized controlled, crossover trial was con-
ducted to assess the efficacy of MTX in chronic CPPD
arthropathy. We found that after three months of treat-
ment, 15 mg of sc MTX, did not significantly improve
the symptoms of CPPD disease, while MTX was associ-
ated with increased AEs typically related to this therapy.
To our knowledge, this is the first PBO-controlled trial
to investigate the efficacy of MTX, an inexpensive and
well-tolerated anti-rheumatic drug, in patients with
chronic CPPD arthropathy.
This controlled study therefore contradicts our prelim-
inary observational study as well as another Spanish report
[6,7]. Several hypotheses can explain the contradiction be-
tween favorable observational findings and a negative trial.
First, this trial was possibly underpowered, leading to
the possibility of a false negative result. Indeed, it proved
extremely difficult to set up a multicenter, multinational,
investigator-based study allowing the recruitment of
Figure 2 Flow diagram of the study. Displays the study flow: 49 patients were screened, 26 corresponded to the inclusion and exclusion
criteria and signed the study informed consent form, 21 (81%) finished the first treatment period and 20 (95%) the second treatment period.
Overall, 25 patients completed the methotrexate (MTX) treatment period and 21 the placebo (PBO) treatment period.
Finckh et al. Arthritis Research & Therapy 2014, 16:458 Page 5 of 8
http://arthritis-research.com/content/16/6/458enough patients. However, because of the crossover de-
sign, the trial still had a predicted power of 74% to detect
a moderate change in DAS44, the study’s primary out-
come. While the possibility of a false negative result exists,
the likelihood that MTX has a large beneficial effect on
the whole spectrum of chronic CPPD arthropathies is low.
Furthermore, our outcome measures might not have
been adequate to capture a potential beneficial effect of
MTX; however, currently no validated outcome mea-
sures are available for the different clinical presentations
of chronic CPPD arthropathy. The fact that MTX did
not demonstrate a significant effect on the primary out-
come, nor any of the five secondary outcomes, strongly
suggests that this is not a false negative result. Another
possible explanation for this finding is that we included
patients not necessarily during a flare, with baseline dis-
ease activity too low (DAS44 between 2 and 3, medianCRP around 3) to demonstrate a large effect size. Further-
more, as the natural course of the disease is one of flares
and spontaneous improvements, a phenomenon of regres-
sion to the mean, makes the demonstration of a beneficial
treatment effect even more difficult. This phenomenon
could be amplified by the fact that flares frequently occur
at intervals longer than three months, especially in pa-
tients with early disease.
In addition, CPPD disease is notoriously heterogeneous
[1] and differential responses to a given medication are
likely. This study has included patients with a variety of
CPPD arthropathy clinical presentations (chronic or recur-
rent arthropathies, mono-, oligo- or poly-articular), which
may have further diluted the study’s ability to demonstrate
an effect of MTX. Another major difficulty is the fact that
this aged population is frequently affected by multiple
coexisting pathologies, including osteoarthritis and other
Table 1 Baseline characteristics at the initiation of the respective treatment periods
Disease characteristics(1),(2) Treatment period
MTX (N = 25)
Treatment period
PBO (N = 21)
P
Age [years], mean ± sd 62.8 ± 13.7 69.3 ± 11.9 0.374
Male sex [%] 44.4 36.4 0.754
Number of tender joints(3), median 4.5 [2.75 – 12.0] 5.5 [2.0 – 9.25] 0.465
Number of swollen joints(4) , median 2.5 [1.0 – 4.75] 2.0 [1.0 – 9.5] 0.782
CRP(5) [mg/l], median 3.0 [2.0 – 7.0] 3.15 [2.0 – 6.93] 0.632
DAS44(6), median 2.5 [1.7 – 3.0] 2.1 [1.7 – 3.1] 0.957
Pain - VAS(7), median 6 [4.75 – 8.25] 6 [5 – 7] 0.270
Physician global assessment(8), median 4.5 [3 – 6.25] 5 [4 – 6] 0.311
Number of analgesics/week(9), median 13.5 [2.0 – 28.0] 10.0 [2.5 – 26.0] 0.684
Number of self-reported flares(10), median 1 [0 – 2] 1 [0 – 1] 0.763
Clinical presentation(11) [N (%)]
Monoarticular 3 (12%) 2 (10%) 0.957
Oligoarticular 10 (40%) 9 (43%)
Polyarticular 12 (48%) 10 (48%)
Persistence of symptoms(12) [N (%)]
Recurrent arthritides (‘pseudogout’) 4 (22%) 7 (39%) 0.471
Chronic arthritides 14 (78%) 11 (61%)
(1)Since this is a crossover trial, patients can contribute both to the MTX and the PBO arm. Patient and disease characteristics are compared at the initiation of the
respective treatment periods, which could either be at T0 or T +5 on Figure 1. (2)Values are given in mean (standard deviations (sd)), in medians (interquartile
ranges), or in absolute numbers (proportions), as indicated. (3)The number of tender joints could range from 0 to 44; (4)the number of swollen joints could range
from 0 to 44; (5)C-reactive protein ranged from 0 to 28, with the normal range being <10; (6)the disease activity score based on 44 joints rages from 0 to 10; (7)the
visual analog scale for pain ranges from 0 to 10; (8)the physician global assessment scale ranges from 0 to 10; (9)patients reported the mean number of analgesic
pills taken during the previous week, ranged from 0 to 50; (10)number of self-reported arthritic flares during the previous month; (11)the clinical presentation was
based on the maximum number of swollen joints during the three- month treatment period; (12)the persistence of symptoms was based on the assessment of the
enrolling physician. This information was not always recorded (missing in eight patients). MTX, methotrexate; PBO, placebo; CRP, C-reactive protein; DAS44, disease
activity score based on 44 joints; VAS, visual analog scale.
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beneficial therapeutic effect. In addition, induction of tran-
sient arthralgias in some patients is a well-recognized ad-
verse effect of MTX [18], which could have further
obscured a potential beneficial effect. Finally, our study de-
sign allowed patients to take auto-medication of analge-
sics, NSAIDs and low-dose glucocorticoids, which may
further have obliterated our capacity to demonstrate a po-
tential treatment effect of MTX.Table 2 Change in outcomes between start of treatment and
Outcomes Treatment cours
(N = 25)
DAS44 −0.08 [−0.6, 0.1]
Number of tender joints [0 – 44] 0 [−1.0, 1.3]
Number of swollen joints [0 – 44] −1 [−3.5, 0]
CRP level 0.2 [−0.8, 1.9]
Number of analgesic pills/week, median 0 [−7, 4]
Number of flares/3 months 0 [−1, 0]
VAS Pain −1 [−2.8, 0]
All results are displayed in medians [interquartile ranges]. MTX, methotrexate; PBO,
protein; VAS Pain, visual analog scale for pain.The crossover design assumes that the effect of the
medication is transitory and removed quickly after treat-
ment discontinuation during the ‘wash-out period’, with
no carry-over effect thereafter. The pharmacological
half-life of MTX is typically around four to six weeks in
healthy individuals, thus a two-month wash-out period
appears adequate. We examined a possible carry-over ef-
fect in the analysis, but did not find any statistically sig-
nificant one. We cannot exclude the possibility that athree months
e: MTX Treatment course: PBO P value
(N = 21)
−0.13 [−0.6, 0.1] 0.44
−1 [−3.5, 0.5] 0.17
0 [−1.5, 2.0] 0.56
−0.3 [−1.6, 1.6] 0.33
0 [−2.0, 1.5] 0.36
0 [−1, 0] 0.10
0 [−2, 1] 0.43
placebo; DAS44, disease activity score based on 44 joints; CRP, C-reactive
Figure 3 Evolution in disease activity. Displays the evolution of
the disease activity as measured by the disease activity score based on
23 joints (DAS28) while receiving either methotrexate (MTX) (N = 25) or
placebo (PBO) (N = 21). This figure aggregates both treatment periods,
before and after the crossover.
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after three months. It is possible also that a dose of 15 mg
of sc MTX was insufficient for some of the patients; it was
selected because this dose of MTX has proved to be effect-
ive in older RA patients [11], and in our preliminary study,
but possibly a higher dosage could have been more effect-
ive. The compliance of the study medication was good, as
the sc injections were either performed by a nurse, at least
in the beginning, and when not, all syringes were verified
after use to control proper emptying. No specific outcome
measures have been validated for CPPD arthropathy, which
forced us to use instruments developed and validated for
other rheumatic conditions. However, the clinical presenta-
tion of complicated CPPD is often similar to other com-
mon rheumatic conditions, such as gout or seronegative
inflammatory arthritis, which should make the use of out-
come measures for these diseases good instruments for
chondrocalcinosis as well.
Famous precedents actually exist on the sometimes
wide discrepancies between observational and controlled
studies, which can be explained by designs of the later
ones that afterward appeared unsuitable to demonstrate
an effect [19]. We therefore strongly believe that further
studies involving more centers and patients, a better se-
lection of the cases, if possible with less comorbidities,
longer treatment periods and a more strictly defined in-
take of other medications is warranted.
Conclusions
Chondrocalcinosis is indeed one of the most common
joint disorders, affecting up to 5% of the humanpopulation, with the prevalence rising to 15% over 60 years
of age [20]; its incidence will continue to rise because of
the increasing age of the population. CPPD disease is cer-
tainly under-recognized, often misdiagnosed and fre-
quently only treated symptomatically, which can lead to
accelerated joint destruction. Existing treatments are often
unsatisfactory and currently no anti-rheumatic therapy
has been formally tested in CPPD arthropathy. The bio-
logic anti-IL-1 agents are promising for some patients, but
certainly do not represent an option for a vast majority of
patients throughout the world at least for a while, in par-
ticular because of their price. Effective, safe and cheap
therapeutic options are therefore clearly needed to im-
prove the quality of life of patients not responding to sim-
ple NSAID therapy. At this time, in view of this study and
other reports [8], MTX is clearly not a treatment solution
for all patients with chronic CPPD arthropathy. However,
some patients continue to take MTX because of strong
perceived benefits, after being informed of their treatment
arm. In addition, MTX may have the potential to reduce
joint damage in chronic CPPD arthropathy, given its
pharmacological properties and established protective ef-
fects in RA [5], and this might be considered as an out-
come in future studies. We therefore believe that MTX,
despite this negative study, is still an option for selected
patients with inadequate response or intolerance to the
other available medications, and that further studies are
warranted.
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